Clinical Trials Logo

Radiotherapy clinical trials

View clinical trials related to Radiotherapy.

Filter by:

NCT ID: NCT05673304 Recruiting - Breast Cancer Clinical Trials

Preoperative Boost Associated With Neoadjuvant Chemotherapy in Luminal B Breast Cancer

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

IBISCO TRIAL is a phase II trial aimed to demonstrate the improvement of pathological complete response (pCR) in Luminal B breast cancer (BC) patients treated with stereotactic radiation therapy (SBRT) as an anticipated boost associated with neoadjuvant chemotherapy (NAC). As a secondary objective, histochemical and molecular analysis of the tumour and the inflammatory microenvironment will be performed.

NCT ID: NCT05622162 Active, not recruiting - Prostate Cancer Clinical Trials

Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7

MIP7
Start date: December 19, 2022
Phase: Phase 3
Study type: Interventional

The present study in patients with Prostate cancer and biochemical failure after surgery and/or radical-postoperative Radio Therapy (RT) will evaluate if PET/CT with 18F-JK-PSMA-7 compared to PET-CT 18F-Choline is able to identify the early pattern of biochemical recurrence and/or metastatic sites, so that the patient could be better managed, with a benefit in survival.

NCT ID: NCT05604950 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma

Surgery Versus Non-surgical Treatment for Esophageal Squamous Cell Carcinoma in Patients Older Than 70 Years

Start date: January 1, 2009
Phase:
Study type: Observational [Patient Registry]

To determine whether older patients who underwent esophagectomy had better outcome survival than those who were non-surgically treated.

NCT ID: NCT05602415 Recruiting - Soft Tissue Sarcoma Clinical Trials

Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma

Start date: November 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of dose reduced postoperative radiotherapy combined with Anlotinib for patients of soft tissue sarcoma

NCT ID: NCT05594069 Completed - Clinical trials for Head and Neck Cancer

Effect of Triple Pre-rehabilitation on Radiotherapy for Head and Neck Cancer Patients

Start date: November 24, 2022
Phase: N/A
Study type: Interventional

To evaluate the intervention effect of triple pre-rehabilitation on head and neck cancer patients with radiotherapy, and process evaluation to further optimize the intervention program. The pre-rehabilitation intervention was develped previously based on the process of evidence-based-nursing, including interventions of nurtrtion, exercise, and psychology.

NCT ID: NCT05554276 Recruiting - Cervical Cancer Clinical Trials

Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer

PD-1
Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

Based on various external factors and differences in the basic characteristics of patients, in my country, it is not clear whether concurrent chemoradiotherapy can achieve optimal therapeutic effect in patients with pathologically diagnosed stage IIB or above locally advanced cervical cancer. Under the limitations of radiotherapy and surgery conditions in the region, some patients will try neoadjuvant chemotherapy combined with PD-1 antibody therapy before standard radiotherapy, hoping to reduce cancer focus and reduce infiltration. Thereby reducing the scope of radiotherapy, better ensure the efficacy of late radiotherapy and chemotherapy and reduce the side effects of radiotherapy. Judging from the review of such patients, neoadjuvant chemotherapy combined with PD-1 antibody therapy + radical radiotherapy seems to have certain efficacy and tolerance in the near future as expected. No statistical analysis has been done on the long-term survival of patients. This topic intends to treat inoperable locally advanced cervical cancer patients with neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy, and explore the treatment-related toxic and side effects and efficacy of neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy. It is hoped that through this study, it will provide a reference for the comprehensive treatment of inoperable locally advanced cervical cancer that has been pathologically diagnosed in the future.

NCT ID: NCT05539144 Completed - Clinical trials for Head and Neck Cancer

A New Delineation Approach for Oral Cavity, Oropharynx, Larynx and Hypopharynx in IMRT for Head and Neck Cancer

Start date: November 11, 2021
Phase: N/A
Study type: Interventional

The investigators tries a new method to delineating the oral cavity, oropharynx, larynx and hypopharynx, and use the head-and-neck region to test whether the method can to create a good IMRT plan, and alleviate the oral radiation injury, reduce the incidence of adverse reactions.

NCT ID: NCT05524012 Recruiting - Radiotherapy Clinical Trials

Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer

PRIMO
Start date: November 30, 2022
Phase:
Study type: Observational

This pilot study aims to trial multimodal early response assessment to enable therapy adaptions in the context of non-operative therapy strategies of locally advanced rectal cancer (LARC) for development of a non-invasive response prediction model.

NCT ID: NCT05515796 Recruiting - Gastric Cancer Clinical Trials

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Start date: September 1, 2022
Phase: Phase 2
Study type: Interventional

immunotherapy,gastric cancer,rectal cancer,biomark

NCT ID: NCT05514327 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This is a single-arm single center study to prospectively evaluate the safety and efficacy of ultra-fraction radiotherapy bridging CAR-T therapy in relapsed/refractory diffuse large b cell lymphoma